Reversal of sleep disturbance in Parkinson's disease by antiparkinsonian therapy

Askenasy, J. J. M.; Yahr, M. D.

doi:10.1212/wnl.35.4.527

Cited by 118 publications

(44 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, poor sleep was positively correlated with the dosage of levodopa and hypnotics in our and two other studies (Antczak et al., 2013; Verbaan, van Rooden, Visser, Marinus, & van Hilten, 2008). Levodopa can improve sleep efficiency with reduced sleep latency by improving motor scores (Askenasy & Yahr, 1985; Ferreira, Prabhakar, & Kharbanda, 2014; Kales, Ansel, Markham, Scharf, & Tan, 1971). Therefore, instead of higher dosage of levodopa leading to poor sleep, it is possible that complaint of poor sleep made poor sleepers in our cohort receive higher dosage of levodopa than good sleepers.…”

Section: Discussionmentioning

confidence: 99%

Sleep disturbances in Taiwanese patients with Parkinson's disease

Lin

Chen

et al. 2017

Brain and Behavior

View full text Add to dashboard Cite

IntroductionSleep disturbance is a common nonmotor symptom of Parkinson's disease (PD) and strongly affects patients’ quality of life. The relationship between excessive daytime sleepiness (EDS) and nighttime problems remains uncertain. Arguments persist regarding the risk factors for sleep disturbance among patients with PD. Furthermore, the prevalence of EDS appears to be lower in Asian countries. Herein, we conducted the study to describe the characteristics of sleep problems in a sample of Taiwanese PD patients and delineate the difference with reported sleep disturbances in Caucasian PD patients from the literature.MethodsPatients with PD were recruited from the outpatient clinic of a tertiary medical center and were evaluated using standardized assessment protocols, including the Parkinson's Disease Sleep Scale (PDSS), the Pittsburgh Sleep Quality Index (PSQI), Epworth Sleepiness Scale (ESS), and 39‐Item Parkinson's Disease Questionnaire (PDQ‐39).ResultsA total of 225 patients with PD were recruited. The mean age of patients with PD was 65.7 years old and the mean disease duration was 8.18 years. Among the patients, 53.8% were defined as poor sleepers (PSQI > 5) and 26.3% had EDS. Seventy‐one percent of the poor sleepers used hypnotic medications. The poor sleepers were worse in the scores of Unified Parkinson's Disease Rating Scale (UPDRS), PDSS, and the PDQ‐39, and received higher levodopa daily dosage. A PDSS score of <126 indicate that a patient with PD was a poor sleeper. EDS was positively correlated with advanced Hoehn and Yahr stages and use of dopamine agonists but not with levodopa daily dosage and levodopa equivalent daily dosage.ConclusionsTaiwanese patients with PD had a lower prevalence of EDS compared with the literatures reported in Caucasian patients. We identify and suggest that PDSS total score, rather than subcategory items, should be used to predict poor sleep among patients with PD.

show abstract

Section: Discussionmentioning

confidence: 99%

Sleep disturbances in Taiwanese patients with Parkinson's disease

Lin

Chen

et al. 2017

Brain and Behavior

View full text Add to dashboard Cite

show abstract

“…Furthermore, the possible effects of anti parkinsonian drugs on sleep patterns have been often neglected, though a relationship between this therapy and sleep changes has been reported [10][11][12].…”

Section: Introductionmentioning

confidence: 99%

Respiration and Heart Rate Variability during Sleep in Untreated Parkinson Patients

Ferini‐Strambi¹,

Franceschi²,

Pinto³

et al. 1992

Gerontology

View full text Add to dashboard Cite

Twenty-six patients with untreated mild to moderate Parkinson’s disease (PD) lasting 5 years or less, were investigated in the sleep laboratory. Sleep architecture and respiration during sleep did not significantly differ from age-matched controls. PD patients showed defective cardiac autonomic control during sleep, mainly parasympathetic but also sympathetic in nature, although they had normal results in conventional autonomic tests during wakefulness. Therefore, autonomic cardiac involvement seems to be an early sign of PD.

show abstract

“…308,328,366,[372][373][374] In other situations they may improve nocturnal immobility, and in this way improve the quality of sleep. 872,873 Thus, dopaminergic medications can either improve or worsen sleep in patients with PD.…”

mentioning

confidence: 99%

The scientific and clinical basis for the treatment of Parkinson disease (2009)

Olanow¹,

Stern²,

Sethi³

2009

Neurology

771

658

View full text Add to dashboard Cite

Parkinson disease (PD) is an age-related neurodegenerative disorder that affects as many as 1-2% of persons aged 60 years and older. With the aging of the population, the frequency of PD is expected to increase dramatically in the coming decades. Current therapy is largely based on a dopamine replacement strategy, primarily using the dopamine precursor levodopa. However, chronic treatment is associated with the development of motor complications, and the disease is inexorably progressive. Further, advancing disease is associated with the emergence of features such as freezing, falling, and dementia which are not adequately controlled with dopaminergic therapies. Indeed, it is now appreciated that these nondopaminergic features are common and the major source of disability for patients with advanced disease. Many different therapeutic agents and treatment strategies have been evaluated over the past several years to try and address these unmet medical needs, and many promising approaches are currently being tested in the laboratory and in the clinic. As a result, there are now many new therapies and strategic approaches available for the treatment of the different stages of PD, with which the treating physician must be familiar in order to provide patients with optimal care. This monograph provides an overview of the management of PD patients, with an emphasis on pathophysiology, and the results of recent clinical trials. It is intended to provide physicians with an understanding of the different treatment options that are available for managing the different stages of the disease and the scientific rationale of the different approaches. 1 PD is the second most common neurodegenerative disorder, with an average age at onset of about 60 years. An estimated 5 million people throughout the world have PD, with 1 million individuals each in the United States and in Europe with the disorder. PD affects approximately 0.3% of the population and 1% to 2% of those older than 60 years.2 With the aging of the population and the substantial increase in the number of at-risk individuals older than 60 years, it is anticipated that the prevalence of PD will increase dramatically in the coming decades.

show abstract

Reversal of sleep disturbance in Parkinson's disease by antiparkinsonian therapy

Cited by 118 publications

References 0 publications

Sleep disturbances in Taiwanese patients with Parkinson's disease

Sleep disturbances in Taiwanese patients with Parkinson's disease

Respiration and Heart Rate Variability during Sleep in Untreated Parkinson Patients

The scientific and clinical basis for the treatment of Parkinson disease (2009)

Contact Info

Product

Resources

About